Next Article in Journal
Dual-Responsive Supramolecular Chiral Assemblies from Amphiphilic Dendronized Tetraphenylethylenes
Next Article in Special Issue
Design, Synthesis, and Antifungal Activity of N-(alkoxy)-Diphenyl Ether Carboxamide Derivates as Novel Succinate Dehydrogenase Inhibitors
Previous Article in Journal
Solvent-Controlled Morphology of Zinc–Cobalt Bimetallic Sulfides for Supercapacitors
Previous Article in Special Issue
Inhibition Mechanism of Chitooligosaccharide-Polyphenol Conjugates toward Polyphenoloxidase from Shrimp Cephalothorax
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 28
Issue 18
10.3390/molecules28186579
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Recent Development of Novel Aminoethyl-Substituted Chalcones as Potential Drug Candidates for the Treatment of Alzheimer’s Disease

by
Pratibha Sharma
1,
Manjinder Singh
1,*,
Varinder Singh
2,
Thakur Gurjeet Singh
1,
Tanveer Singh
3 and
Sheikh F. Ahmad
4
1
Chitkara College of Pharmacy, Chitkara University, Rajpura 140401, Punjab, India
2
Department of Pharmaceutical Sciences and Technology, Maharaja Ranjit Singh Punjab Technical University, Bathinda 151001, Punjab, India
3
Department of Neuroscience and Experimental Therapeutics, College of Medicine, Texas A & M Health Science Center, College Station, TX 77807, USA
4
Department of Pharmacology and Toxicology, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia
*
Author to whom correspondence should be addressed.
Molecules 2023, 28(18), 6579; https://doi.org/10.3390/molecules28186579
Submission received: 20 August 2023 / Revised: 4 September 2023 / Accepted: 7 September 2023 / Published: 12 September 2023
(This article belongs to the Special Issue Enzyme Inhibitors: Design, Synthesis and Biological Evaluation, 2nd Edition)
Browse Figures
Versions Notes

Abstract

:
No drug on the market, as a single entity, participates in different pathways involved in the pathology of Alzheimer’s disease. The current study is aimed at the exploration of multifunctional chalcone derivatives which can act on multiple targets involved in Alzheimer’s disease. A series of novel aminoethyl-substituted chalcones have been developed using in silico approaches (scaffold morphing, molecular docking, and ADME) and reported synthetic methods. The synthesized analogs were characterized and evaluated biologically using different in vitro assays against AChE, AGEs, and radical formation. Among all compounds, compound PS-10 was found to have potent AChE inhibitory activity (IC50 = 15.3 nM), even more than the standard drug (IC50 = 15.68 nM). Further, the in vivo evaluation of PS-10 against STZ-induced dementia in rats showed memory improvement (Morris Water Maze test) in rats. Also, PS-10 inhibited STZ-induced brain AChE activity and oxidative stress, further strengthening the observed in vitro effects. Further, the molecular dynamic simulation studies displayed the stability of the PS-10 and AChE complex. The novel aminoethyl-substituted chalcones might be considered potential multifunctional anti-Alzheimer’s molecules.

Graphical Abstract

1. Introduction

Chalcone, a naturally occurring compound, is the precursor of flavonoids and isoflavonoids and an important constituent of various natural products [1,2]. Chalcone-based derivatives exhibit diverse biological effects, including anti-inflammatory [3,4,5] anticancer [6,7,8,9,10,11], antimalarial [12,13], antidiabetic [14,15,16], antioxidant [17,18], and antimicrobial [19,20]. They are also known for their actions on CNS such as acetylcholinesterase (AChE) and butyrylcholinestrase (BuChE), lipid peroxidation reduction, GABA modulation, and monoamine oxidase inhibition [21,22,23,24,25]. Due to this multi-functional potential, chalcone-based compounds have the ability to manage various complex brain diseases, including Alzheimer’s disease (AD).
AD involves the cascade of anomalies including Aβ aggregates, tau protein hyper-phosphorylation associated with cellular microtubules, and the generation of neurofibrillary tangles (NFTs). Consequently, these anomalies are responsible for several physiological problems such as synaptic damage and increased radical generation and inflammation. Apart from this, the central cholinergic neurons are also severely affected, leading to decreased acetylcholine levels. As a result, a number of physiological activities are affected, such as cognition, thinking ability, language, dependency, and memory functions [26,27]. Moreover, there is evidence proving the effect of oxidative impairment on the endorsement of amyloid aggregates and NFT formation in AD [28]. The large amounts of Fe2+ and Cu2+ in the brain hasten ROS formation, which further causes Aβ neurotoxicity. Also, the high levels of receptive carbonyls and oxygen radicals lead to AGEs, which cross-link and cause glycation of the tau and Aβ or proteins, ultimately inducing neuron cell death [29].
Although a number of potential targets leading to AD have been identified, only AChE inhibitors (AChEIs) could pave their way into clinics for managing AD. However, these drugs are effective symptomatically, but unable to avert the disease movement [30,31]. Aducanumab, a monoclonal-antibody-based medication that targets the oligomers as well as insoluble fibrils of Aβ plaques, was recently approved by the FDA. It is indicated for patients with mild cognitive impairment [32]. Despite the known multi-etiologies associated with AD, it has been observed that the majority of research is focused on developing molecules that could target one aspect of AD [33,34,35,36]. Such drugs that are single-target-oriented only enable a palliative treatment rather than curing or preventing neurodegenerative multifactorial AD. This could be one of the reasons for the limited success of AChEIs in clinical practice.
Thus, the development of molecules that have the ability to modulate different key targets of AD simultaneously seems to be the appropriate tool to tackle AD. Further, the compounds having multifunctional potential may have a higher value in terms of their potency due to synergism or limited side effects. This encouraged us to design and develop molecules that could act on different key areas of AD. The research on the development of chalcone-based multifunctional molecules having varied substituents in different positions has been accelerated in recent years (Figure 1) [21,22,23,24,25,26,37,38,39].
Various substitutions on the chalcone skeleton reflect the anti-Alzheimer’s potential in terms of AChE inhibition, MAO-B inhibition, amyloid aggregation inhibition, and antioxidant properties [20,22]. Therefore, chalcone-based novel analogs could be used and taken as a lead for the management of AD. From comprehensive literature analysis, it has been found that no chalcone-based multi-functional molecule is available in clinical practice to manage AD.
The current study involves the design, synthesis, and biological evaluation of chalcone or 1,3-diaryl-2-propen-1-one substituted with varied tertiary amines at ring-B via two carbon spacers. A novel series of aminoethyl-O-chalcone by-products were developed using Claisen Schmidt condensation [40,41] and employed for AChE, AGEs, and free radical inhibitory potential in vitro. The most potent developed molecule was further tested in vivo using an STZ-induced rat model of dementia. Also, brain biochemical estimations were performed to delineate the mechanism of action.

2. Results and Discussion

2.1. Scaffold-Morphing-Based Bioisosteric Replacement

The bioisosteric replacement of chalcone was performed by manual design as well as with a web server (MolOpt) to generate corresponding analogs with their pharmacokinetics and pharmacodynamics. The manual design was based on certain substitutions like the presence of alkoxy groups essential for BBB permeation, and the incorporation of tertiary amines and chain elongation is beneficial for inhibiting AChE. As a result, five potential bioisosteric replacement sites were produced. A total of 826 molecules were generated by the bioisosteric replacement at these five sites (Figure 2). On the basis of synthetic accessibility, the top 40 analogs were used in the pharmacokinetic studies.

2.2. ADME Studies

The ADME studies of the top 40 molecules were carried out using SwissADME software (http://www.swissadme.ch/, accessed on 3 January 2021). The leading novel chalcone molecules were identified on the basis of their drug-like properties. All the screened molecules were drug-like molecules as per Lipinski’s rule of five (HB donor ≤ 5, HB acceptor ≤ 10, logPo/w < 5, MW < 500). These drug-like properties are critical for BBB (blood–brain barrier) permeability and, subsequently, the activity of CNS. These molecules displayed a crucial ADME profile with rationalized physicochemical and pharmacokinetic properties (Table 1). The parameters including TPSA, Log P consensus, and Log S ESOL indicated the polarity, lipophilicity, and solubility of the analogs. Further, all molecules exhibited high gastrointestinal absorption, ensuring their significant bioavailability. The anticipated ADME (Absorption, Distribution, Metabolism, and Excretion) profile indicated that all of the highest-ranking molecules possessed drug-like characteristics.

2.3. Molecular Docking Studies

AChE is composed of a long channel split into two parts: the peripheral anionic site (PAS) and the catalytic anionic site (CAS). Within the PAS, the amino acids Trp279, Arg289, and Phe330 play critical roles. Meanwhile, the CAS features the catalytic triad consisting of Ser200, Glu327, and His440, along with other significant amino acids like Trp84, Gly119, and Tyr121 [42]. Docking analysis for the screened chalcone molecules was carried out to investigate their interaction with the active gorge of the AChE. The PS1 was also subjected to docking analysis in order to analyze the interactions of the common moiety with the AChE protein. All the molecules had good binding energies and crucial interactions with the amino acids at both sites (CAS and PAS) of the AChE enzyme. Interestingly, all the analogs have good docking scores as compared to the standard drug (−51.89 Kcal/mol). All of the molecules showed interactions with the His440 and Ser200 residues of the catalytic triad via Pi-alkyl interactions, C-H bond formation, or Van der Waals interactions, including key interactions with Trp84, Gly119, and Tyr121. These molecules also interacted via Phe330, Tyr130, Trp279, and Arg289 of PAS. However, PS1 lags in terms of binding affinity (−31.90 Kcal/mol) toward the binding site, possibly due to the absence of amine groups and thus relatively smaller size. The binding energies of PS4, PS5, and PS (8–10) (−52.28 to −63.75 Kcal/mol) were better than the donepezil. Although PS3, PS6, and PS7 showed similar binding energy levels (−51.01 to −51.43 Kcal/mol) as donepezil, they interacted with more of the key amino acids. The designed analogs showed significant interactions at both active subsites of AChE, namely PAS (Phe330, Tyr130, Trp279, and Arg289) and CAS (Trp84, Gly119, Tyr121). The docking analysis suggests that the presence of varied amines alters the compounds’ binding affinity with enzymes. The dimethyl-substituted analog (PS2) exerted the least binding energy (−49.39 Kcal/mol) compared to the other amine-substituted analogs. The leading analogs with isosteric replacements were identified (Table 2) and were subjected to synthesis and biological evaluations.

2.4. Binding Mode and Interactions of PS5 and PS10 with AChE

The interactions of the most potent in vitro AChE inhibitors (PS5 and PS10) with the crucial residues are displayed in Figure 3. The binding of compound PS5 extended from CAS to PAS in the active site gorge. The carbonylic oxygen formed an H-bond with Arg 289. The quaternary nitrogen of piperidine moiety displayed π–cationic interactions with Trp84, Phe330, and Asp72. The π–alkyl interaction was formed between the carbon atom of piperidine and His440. It additionally created a single hydrogen bond with Arg289 via carbonyl oxygen.
The compound PS10 underwent pi–pi stacking interactions of both phenyl rings with Trp279 in the acyl binding pocket and Phe334 residue in the PAS, respectively. It formed an H-bond with Phe288 via carbonyl oxygen. Both quaternary nitrogen atoms of 4-methylipiperazine moiety displayed π–cationic interactions with Trp84, Asp72, and Glu199. The docking results revealed the binding capacity of selected molecules with the CAS and PAS residues through the formation of H-bonds; π–π (aromatic), π–cationic, and hydrophobic interactions; and the attractive charges with the AChE active gorge.

2.5. Chemistry

The synthetic methodologies employed to synthesize intermediate (1) and final compounds PS(1–10) are given in Scheme 1. The compound PS1 was synthesized according to the well-established Claisen Schmidt condensation reaction with slight modifications. Further, the prime intermediate (1) was synthesized by alkylation of PS1 with 1,2-dibromoethane in acetonitrile. The incorporation of various secondary amines into intermediate (1) in the presence of K2CO3 in acetonitrile afforded target compounds PS(2–10). The reaction was monitored with TLC plates.

2.6. Biological Activity

2.6.1. In Vitro AChE Inhibition Studies

The ability of target compounds PS(1–10) to inhibit AChE was evaluated by the slightly modified Ellman’s method [43]. The objective of attaching different amines to the 1,3-diphenylprop-2-enone skeleton via an ethoxy spacer was to enhance the interaction of the designed synthesized chalcones with both the PAS and CAS of AChE. Interestingly, most of the tested compounds PS(1–10) had significant AChE inhibitory activity (Table 3). The compounds PS10 and PS5, which had 4-methylpiperazine and piperidine amines attached to chalcone moiety, were found to be the most effective AChE inhibitors with IC50 values of 15.3 and 19.71 nM, respectively.
The resulting data showed that the terminal amino group significantly influenced the AChE inhibition. The six-membered cyclic amine-substituted derivatives PS5, PS6, PS7, and PS10 (IC50 = 15.3–22.72 nM) showed better AChE activity than the five-membered cyclic amines PS8 and PS9 (IC50 = 32.72; 26.3 nM). Further, the aliphatic amine-substituted compounds PS2, PS3, and PS4 showed moderate inhibition with IC50 values of 52.51, 47.5, and 48.8 nM. This may be due to improper fitting of the five-membered ring systems as well as the aliphatic amines inside the enzyme.
Particularly, the 4-methylpiperazine derivative (PS10) was the most potent AChE inhibitor, with IC50 = 15.3 nM, comparable to donepezil (IC50 = 15.68 nM) and more potent than the unsubstituted piperazine derivative (PS6, IC50 = 21.4 nM). The aliphatic amine-based derivatives were less effective across the series.

2.6.2. AGE Formation Inhibitory Activity

The synthesized compounds markedly inhibited AGE formations in vitro (Table 3). The compound PS1 (IC50 = 43.6 µM) was the most active among all and showed comparable inhibition to the positive control (IC50 = 44.3 µM), while the compounds PS(2–4), PS6, and PS(8–9) (IC50 = 64.51–69.39 µM) were inferior inhibitors compared to the positive control. The compound PS10 with 4-methylpiperazine had better anti-glycating effects compared to the unsubstituted piperazine compound (PS6). The six-membered cyclic amines (PS5, PS6, PS7, and PS10) were more active than five-membered (PS8 and PS9). The compounds with dimethyl amine (PS2), diethyl amine (PS3), and N-benzylmethylamine moiety (PS4) exhibited lower activity ranging from IC50 = 67.3 to 69.39 µM.

2.6.3. In Vitro Antioxidant Activity

The antioxidant activity showed that all synthesized compounds exhibited significant radical scavenging activity owing to the presence of an α,β-unsaturated carbonyl system that extended the resonance effect from one ring to another (Table 3). PS10 was reported as the most potent (EC50 = 22.83 nM) and comparable to the standard (EC50 = 21.7 nM). Further, PS1 also exerted comparable free radical scavenging activity (EC50 = 22.41 nM) due to the added antioxidant property of the hydroxy group. The compounds PS5 and PS7 also showed good radical scavenging activity with EC50 values of 34.38 and 37.65 nM, respectively. The free –NH groups enhanced the free radical scavenging along with an α,β-unsaturated carbonyl system due to its electron-rich environment. The rest of the compounds exhibited moderate radical scavenging activity (EC50 = 46.7–49.85 nM).

2.6.4. In Vivo Activity

The STZ model (i.c.v., 3 mg/kg) is commonly used to study AD in animals [44,45,46]. The intracerebroventricular injection of STZ, at two sub-diabetogenic doses, induces a range of symptoms including impaired cognition, metabolic and molecular changes, and neuropathological symptoms in rodents which are often found in AD subjects. STZ has been found to disrupt cellular energy metabolism and induce mitochondrial changes, resulting in the generation of ROS [47]. The ROS produced can cause damage to the myelin sheath and acetyl coenzyme-A in the hippocampus. As a result, there is an increase in AChE activity, leading to behavioral disturbances, as in Alzheimer’s disease [48,49,50,51]. Thus, this model is frequently used for AD interventions.
MWM is the most commonly used method to measure learning and spatial memory in rats [52,53]. MWM utilizes the natural swimming ability of rats [53,54]. As a result, during the retrieval phase, there is no induced stress that could affect the results. The MWM model is commonly used to test drugs that enhance memory and provide neuroprotection. Thus, it has been used to understand the effect of PS10 on the memory of animals with induced cognitive impairment by means of restoring the ELT.
Previous studies have shown that STZ (i.c.v) administration impairs cognitive function in rodents [55]. Consistent with these findings, our study also found declined memory and learning ability in the STZ group than the control animals, which was significantly reversed by treatment with PS10. This beneficial effect of PS10 may be attributed to the structural aspects of chalcone-based compounds, which have been reported as memory enhancers. The administration of PS10 significantly decreased STZ-induced cognitive impairment by means of restoring the ELT (Figure 4) and TSTQ (Figure 5).
The central cholinergic system is critical for cognitive function, and AD patients often suffer from cholinergic hypofunction due to increased AChE activity and the degeneration of cholinergic neurons [55]. Animal studies have shown that the administration of STZ (i.c.v) increases brain AChE activity, which leads to cognitive impairment and memory deficits [56]. Similarly, in the current study, STZ-administered rats showed higher cerebral AChE activity, which was restored in PS10-treated groups (Figure 6). Flavonoids have been shown to inhibit AChE activity by binding strongly to the enzyme’s active sites through interactions with crucial amino acids of AChE, given in Table 2 [57,58,59,60]. Possibly, due to these interactions between PS10 and amino acids of AChE, PS10 was able to inhibit AChE activity.
Another crucial factor that contributes to the progression of AD is oxidative stress [61,62]. The brain is more vulnerable to oxidative damage compared to other organs due to its high energy demand, relatively lower level of antioxidant defense mechanisms, and high concentration of polyunsaturated fatty acids [62]. STZ injection generates free radicals that overwhelm the brain’s defensive antioxidant system (GSH) and cause lipid membrane oxidation, leading to the production of malondialdehyde [61,63,64]. Thus, in order to analyze the antioxidant property of PS10, the levels of TBARS and GSH were measured in the current investigation (Figure 6). STZ injection was found to increase TBARS and decrease GSH levels in the brain, but these effects were reversed by PS10 treatment. Previously, antioxidant flavonoids have been reported to exhibit cognitive improvement and neuroprotective effects in a variety of neurological disorders [65,66]. Our study suggests that PS10 possesses antioxidant properties that reduce lipid peroxidation and spare the antioxidant enzyme GSH, contributing to the memory improvement effects in STZ-induced animals.

2.7. Molecular Dynamic Simulation Analysis

The stability of the ligand–protein complex was analyzed using a simulation-based interaction protocol. The MD simulation involved the interactions between ligand and protein in dynamic motion and assessed the induced conformational changes at the AChE pocket by ligand binding. The PS-10 and AChE complex was employed for MD studies. The important interactions were retained throughout the MD simulations with slightly different patterns (Figure 7). Compound PS-10 interacted with the key residues (Asp72, Arg289, Trp279, and Tyr334) in the active site via ionic and hydrophobic interactions. It formed an H-bond with Asp72 via carbonyl oxygen.
After the MD simulation, the trajectory of the compound was determined by means of RMSD. The RMSD plot indicated that the docked complex remained stable, with minor fluctuations within 1 °A throughout the simulation-induced cognitive impairment by means of restoring PS10 against AChE. Further, root mean square fluctuation (RMSF) plots for protein were also obtained (Figure 7). The vertical green bars represent the interacting protein residues with ligands during simulation.

3. Material and Methods

3.1. Scaffold Morphing

Scaffold morphing, a technique for drug designing, has been used for the design of novel chalcone molecules. It provides rationalized structural modifications within the parent molecule with improved physicochemical properties [67,68]. This study was carried out using the web server MolOpt (https://xundrug.cn/molopt accessed on 5 January 2021) recently developed web tool for scaffold morphing for bioisosteric transformation [69]. The transformation involves the replacement of the functional groups or other parts of the molecule with their bioisosteres on key molecules. By manually designing and ‘data mining’ an inbuilt module of MolOpt, the five replaceable sites of the designed chalcone compound were generated. The molecules that were produced were evaluated to determine if they could be feasibly synthesized. The feasibility of synthesis was rated from 1 (very easy) to 10 (very difficult), and a threshold of 2.5 was used to screen the molecules. The best molecules were then subjected to pharmacokinetic and molecular docking analyses using computational methods.

3.2. Prediction of In Silico Pharmacokinetic Properties

The kinetic profiles of designed chalcone molecules, i.e., ADME, were predicted using SwissADME, a free web application for analyzing the pharmacokinetic profile of a molecule [70]. Various parameters such as physicochemical properties, lipophilicity, and solubility patterns are predicted on the basis of topological polar surface area (TPSA), consensus logP, and ESOL LogS; additionally, Lipinski’s rule of five (molecular weight and H-bond modulator) for the drug-likeness assessment was considered [71]. The gastrointestinal absorption and brain permeability of the target molecules were also assessed [72,73]. The details of the current study are outlined in Figure 8.

3.3. Molecular Docking

Biovia Discovery Studio software (2019) was used to carry out the molecular docking experiments. To begin the process, the 3D X-ray crystal structure of acetylcholinesterase (AChE) with a PDB ID of 1EVE (2.50 Å) was obtained from the Protein Data Bank (www.rcsb.org, accessed on 10 January 2021). The structures were then preprocessed, prepared, and optimized using the ‘Macromolecule’ module. The protein preprocessing was carried out by the removal of water molecules and heteroatoms, and protonation using the ‘Add Polar’ option. Next, the preparation and generation of binding sites around the co-crystallized ligands was achieved using the ‘Define and Edit Binding Site’ tool. The SMILES notations and structures of the molecules and donepezil were prepared using MarvinSketch and ChemDraw 16.0 software. Ligands were prepared and minimized using the ‘Full Minimization’ of the ‘Small Molecules’ module. The docking analysis was performed using the ‘Dock Ligands (CDOCKER)’ protocol. The native ligand, donepezil (standard drug), was also re-docked at the active site of the AChE, and we compared the interaction behavior with the designed molecules. The molecular interactions of docked complexes of all the molecules with AChE were analyzed by visual inspection. The preparation and generation of binding sites around the co-crystallized ligands were dependent on the docking scores of AChE amino acids.

3.4. Chemistry

All chemicals were taken from marketable suppliers and were used as such. A magnetic stirrer, hot plate (Remi), and rotary evaporator (Perfit) were used for solvent evaporation and recovery. The progression and completion of all the chemical reactions were checked using TLC. Silica columns were employed to purify synthesized compounds followed by melting point determination.
General procedure for the synthesis of (PS1): The mole equivalents of acetophenone and p-hydroxybenzaldehyde were stirred with reflux at 60 °C for 72 h in methanol under mildly acidic conditions to afford PS1. The crude product was treated with water and dried. The compound was recrystallized with alcohol (Scheme 1).
General procedure for the synthesis of PS-1: 3-(4-Hydroxyphenyl)-1-phenylprop-2-en-1-one (2 mmol) (PS-1) and 1,2-dibromoethane (2 mmol) were stirred in acetonitrile in the presence of anhydrous potassium carbonate (10 mmol). The solvent was evaporated and the crude product was thoroughly washed with water, and dried. Then, intermediate 1 was purified on a silica column using hexane:ethylacetate (8:2) as a solvent system.
General procedures for the synthesis of final compounds PS-2 to PS-10: To a solution of intermediate 1 (0.5 mmol) in acetonitrile, different amines (1.0 mmol) and anhydrous K2CO3 (2.5 mmol) were added. After stirring for 48 h, the solvent was removed under vacuum and the crude product was washed with water, filtered, and dried, and then purified on silica columns using CHCl3:MeOH (9:1) as a solvent system. The various spectra’s can be found in Supplementary Materials.
  • 3-(4-Hydroxyphenyl)-1-phenylprop-2-en-1-one (PS-1): Solid crystalline, yellow, yield 70%, m.p.: 187–189 °C; 1H NMR (500 MHz, CDCl3, δ ppm): 8.01–7.99 (2H, m, ArH), 7.79–7.76 (1H, d, J = 15.65 Hz, -CH), 7.58–7.55 (3H, d, m, ArH), 7.51–7.48 (2H, t, J1 = 7.85, J2 = 7.25 Hz, ArH), 7.42–7.39 (1H, d, J = 15.65 Hz, -CH), 6.90–6.88 (2H, m, ArH), 5.52 (1H, brs, OH). 13C NMR (500 MHz, DMSO, δ ppm): 188.87, 160.07, 144.40, 137.86, 132.6, 130.85, 128.54, 128.18, 125.62, 118.35, 115.71; IR(KBr): 3500–3100 cm−1 (-OH str, m); 1647 cm−1 (C=O, s); 1591 cm−1 (Ar C=C, s). MS (ESI) m/z = 225.11 (M + H)+. Rf value: 0.42 (hexane:ethylacetate, 7:3).
  • 3-(4-(2-Bromoethoxy)phenyl)-1-phenylprop-2-en-1-one (1): Solid crystalline white, yield 70%, m.p.: 86–87 °C; 1H NMR (500 MHz, CDCl3, δ ppm): 8.01–7.99 (2H, d, J = 7.8 Hz, ArH), 7.78–7.75 (1H, d, J =12.52 Hz, -CH), 7.62–7.55 (3H, m, ArH), 7.51–7.48 (2H, t, J1 =7.75, J2 = 7.35 Hz, ArH), 7.44–7.40 (1H, d, J = 15.65 Hz, -CH), 6.95–6.93 (2H, d, J = 8.7 Hz, ArH), 4.34–4.31 (2H, t, J1 = J2 = 6.25 Hz, -CH2), 3.66–3.63 (2H, t, J1 = J2 = 6.25 Hz, -CH2), 13C NMR (500 MHz, CDCl3, δ ppm): 190.61, 160.58, 144.62, 138.49, 132.54, 130.26, 128.57, 128.43, 127.97, 120.12, 114.94, 65.02, 29.96; IR(KBr, cm−1): 3059 cm−1 (=C-H str, m); 1645 cm−1 (C=O) (s); 1605 cm−1 (Ar C=C str, m); MS (ESI) m/z = 331.03 (M + H)+. Rf value: 0.38 (hexane:ethylacetate, 8:2).
  • 3-(4-(2-(Dimethylamino)ethoxy)phenyl)-1-phenylprop-2-en-1-one (PS-2): Intermediate 1 was treated with dimethylamine according to the general procedure to give the desired product PS-2 as yellow, solid, yield 60%, m.p.: 92–95 °C; IR(KBr, cm−1): 1655 cm−1 (C=O, s); 1596 cm−1 (Ar C=C str, s), 1300–1100 cm−1 (C-N, m); 1H NMR (500 MHz, CDCl3, δ ppm): 7.90–7.89 (2H, d, J = 7.82, 1.35 Hz, ArH), 7.68–7.65 (1H, d, J = 15.65 Hz, -CH), 7.49–7.43 (3H, m, ArH), 7.40–7.36 (2H, m, ArH), 7.32–7.29 (1H, d, J = 15.65 Hz, -CH), 6.85–6.83 (2H, d, J = 8.7 Hz, ArH), 4.02–3.98 (2H, m, -CH2), 2.64–2.62 (2H, t, J = 5.65, 5.7 Hz, -CH2), 2.23–2.21 (m, 6H, N(CH3)2), 13C NMR (500 MHz, CDCl3, δ ppm): 190.62, 158.65, 144.45, 138.46, 132.27, 130.24, 128.44, 128.33, 127.22, 119.81, 114.73, 66.48, 61.63, 46.12; MS (ESI) m/z = 296.16 (M + H)+. Rf value: 0.62 CHCl3:MeOH, 9:1).
  • 3-(4-(2-(Diethylamino)ethoxy)phenyl)-1-phenylprop-2-en-1-one (PS-3): Intermediate 1 was treated with diethylamine according to the general procedure to give the desired product PS-3 as light yellow, solid, yield 55%, m.p.: 89–91 °C; IR(KBr, cm−1): 1655 cm−1 (C=O, s); 1590 cm−1 (Ar C=C str, s), 1300–1100 cm−1 (C-N, m); 1H NMR (500 MHz, CDCl3, δ ppm): 7.93–7.92 (2H, d, J = 7.4 HZ, ArH), 7.72–7.68 (1H, d, J = 15.7 Hz, -CH), 7.55–7.47 (3H, m, ArH), 7.43–7.31 (3H, m, ArH, -CH), 6.86–6.85 (2H, d, J = 8.55 Hz, ArH), 4.04–4.02 (2H, t, J1 = J2 = 6.25 Hz, -CH2), 2.85–2.83 (2H, t, J1 = J2 = 6.1 Hz, -CH2), 2.62–2.57 (4H, q, J1 = J2 = J3 = 7.1 Hz, 2(-CH2)), 1.02–1.00 (6H, t, J1 = J2 = 7.1 Hz, 2(-CH3)); 13C NMR (500 MHz, CDCl3, δ ppm): 190.61, 160.58, 144.12, 138.44, 132.34, 130.24, 128.54, 128.33, 127.21, 119.79, 114.71, 66.11, 61.62, 46.12, 15.06; MS (ESI) m/z = 324.19 (M + H)+. Rf value: 0.56 (CHCl3:MeOH, 9:1).
  • 3-(4-(2-(Benzyl(methyl)amino)ethoxy)phenyl)-1-phenylprop-2-en-1-one (PS-4): Intermediate 1 was treated with N-benzylmethylamine according to the general procedure to give the desired product PS-4 as yellow, solid, yield 55%, m.p.: 115–117 °C; IR(KBr, cm−1): 1655 cm−1 (C=O, s); 1590 cm−1 (Ar C=C str, s), 1300–1100 cm−1 (C-N, m); 1H NMR (500 MHz, CDCl3, δ ppm): 8.01–7.99 (2H, d, J = 7.35, 1.35 Hz, ArH), 7.79–7.76 (1H, d, J = 15.5 Hz, -CH), 7.62–7.55 (3H, m, ArH), 7.52–7.45 (2H, m, ArH), 7.44–7.39 (1H, d, J = 15.45 Hz, -CH), 7.34–7.30 (3H, m, ArH), 7.27–7.25 (2H, d, J = 8.15 Hz, ArH), 6.92–6.90 (2H, d, J = 8.15 Hz, ArH), 4.14–4.12 (2H, t, J = 6.25 Hz, -CH2), 3.63 (2H, s, -CH2), 2.87–2.84 (2H, t, J = 5.75 Hz, -CH2), 2.36 (3H, s, -CH3); 13C NMR (500 MHz, CDCl3, δ ppm): 190.55, 160.94, 144.74, 138.54, 138.34, 130.37, 130.24, 129.12, 128.58, 128.44, 128.33, 127.22, 119.81, 117.13, 115.01, 66.48, 62.68, 55.56, 42.95; MS (ESI) m/z = 372.19 (M + H)+; Rf value: 0.51 (CHCl3:MeOH, 9:1).
  • 1-Phenyl-3-(4-(2-(piperidin-1-yl)ethoxy)phenyl)prop-2-en-1-one (PS-5): Intermediate 1 was treated with N-benzylmethyl amine according to the general procedure to give the desired product PS-5 as light brown, solid, yield 63%, m.p.: 89–91 °C; IR(KBr, cm−1): 1655 cm−1 (C=O, s); 1590 cm−1 (Ar C=C str, s), 1300–1100 cm−1 (C-N, m); 1H NMR (500 MHz, CDCl3, δ ppm): 8.02–7.99 (2H, m, ArH), 7.79–7.76 (1H, d, J = 15.65 Hz, -CH), 7.63–7.55 (3H, m, ArH), 7.51–7.48 (2H, m, ArH), 7.42–7.39 (1H, d, J = 15.65 Hz, -CH), 6.94–6.93 (2H, d, J = 8.75, ArH), 4.18–4.15 (2H, t, J = 6 Hz, -CH2), 2.83–2.81 (2H, t, J = 5.9 Hz, -CH2), 2.55 (4H, s, 2(CH2)), 1.65–1.46 (6H, m, 3(CH2)); 13C NMR (500 MHz, CDCl3, δ ppm): 190.61, 160.90, 144.71, 138.54, 132.55, 130.22, 128.57, 128.43, 127.71, 119.85, 115.04, 66.04, 57.72, 55.05, 25.79, 24.06; MS (ESI) m/z = 336.20 (M + H)+; Rf value: 0.51 (CHCl3:MeOH, 9:1).
  • 1-Phenyl-3-(4-(2-(piperazin-1-yl)ethoxy)phenyl)prop-2-en-1-one (PS-6): Intermediate 1 was treated with piperazine according to the general procedure to give the desired product PS-6 as light yellow, solid, yield 65%, m.p: 96–99 °C; IR(KBr, cm−1): 1655 cm−1 (C=O, s); 1596 cm−1 (Ar C=C str, s), 1300–1100 cm−1 (C-N, m); 1H NMR (500 MHz, CDCl3, δ ppm): 8.01–7.99 (2H, m, ArH), 7.88–7.86 (1H, d, J = 11.95 Hz, -CH), 7.80–7.74 (2H, m, ArH), 7.52–7.47 (2H, m, ArH), 7.18–7.14 (1H, m, ArH), 7.00–6.98 (1H, d, J = 8.7 Hz, -CH), 6.94–6.92 (2H, d, J = 8.7, ArH), 4.16–4.14 (2H, t, J = 5.8 Hz, -CH2), 2.93–2.91 (4H, t, J = 4.7 Hz, 2(CH2)), 2.82–2.80 (2H, t, J = 5.8 Hz, -CH2), 2.77–2.75 (4H, t, J = 5.7 Hz, 2(CH2)), 2.65 (1H, s, NH); 13C NMR (500 MHz, CDCl3, δ ppm): 190.60, 160.88, 144.68, 138.51, 132.57, 130.23, 128.54, 128.42, 127.74, 119.87, 115.04, 66.00, 57.68, 54.89, 45.97; MS (ESI) m/z= 337.19 (M + H)+; Rf value: 0.25 (CHCl3:MeOH, 9:1).
  • 3-(4-(2-Morpholinoethoxy)phenyl)-1-phenylprop-2-en-1-one (PS-7): Intermediate 1 was treated with morpholine according to the general procedure to give the desired product PS-7 as light pink, solid, yield 55%, m.p.: 104-106 °C; IR(KBr, cm−1): 1655 cm−1 (C=O, s); 1591 cm−1 (Ar C=C str, s), 1300–1100 cm−1 (C-N, m); 1H NMR (500 MHz, CDCl3, δ ppm): 8.01–8.00 (2H, d, J = 6.45 Hz, ArH), 7.79–7.76 (1H, d, J = 15.65 Hz, -CH), 7.62–7.55 (3H, m, ArH), 7.51–7.48 (2H, t, J = 7.55, 7.35 Hz, ArH), 7.44–7.39 (1H, d, J = 15.65 Hz, -CH), 6.94–6.93 (2H, d, J = 8.55 Hz, ArH), 4.17–4.15 (2H, t, J = 5.55 Hz, -CH2), 3.75–3.73 (4H, t, J = 4.4 Hz, 2(CH2)), 2.84–2.82 (2H, t, J = 5.55 Hz, -CH2), 2.59 (4H, s, 2(CH2)); 13C NMR (500 MHz, CDCl3, δ ppm): 190.58, 160.78, 144.61, 138.51, 132.58, 130.23, 128.58, 128.43, 127.83, 119.93, 115.10, 66.88, 65.95, 57.51, 54.10; MS (ESI) m/z = 338.20 (M + H)+; Rf value: 0.36 (CHCl3:MeOH, 9:1).
  • 1-Phenyl-3-(4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)prop-2-en-1-one (PS-8): Intermediate 1 was treated with pyrrolidine according to the general procedure to give the desired product PS-8 as dark brown, solid crystalline, yield 50%, m.p: 105-107 °C; IR(KBr, cm–1): 1655 cm–1 (C=O, s); 1591 cm–1 (Ar C=C str, s), 1300–1100 cm–1 (C-N, m); 1H NMR (500 MHz, CDCl3, δ ppm): 7.65–7.50 (3H, m, ArH, -CH), 7.44–7.40 (2H, t, J = 7.8 Hz, ArH), 7.37–7.32 (1H, m, ArH), 7.21–7.19 (2H, d, J = 8.55 Hz, ArH), 6.99–6.97 (2H, d, J = 8.6 Hz, ArH) or 6.99–6.94 (2H, m, ArH), 6.71–6.68 (1H, d, J = 14.35 Hz, -CH), 4.17–4.14 (2H, t, J = 5.9 Hz, CH2), 2.95–2.92 (2H, t, J = 6 Hz, CH2), 2.80–2.56 (4H, m, 2(CH2)), 1.95–1.76 (4H, m, 2(CH2)); 13C NMR (500 MHz, CDCl3, δ ppm): 199.49, 158.32, 148.56, 142.73, 135.48, 130.16, 128.76, 127.41, 126.19, 125.14, 114.88, 67.00, 55.04, 54.66, 23.49; MS (ESI) m/z = 322.18 (M + H)+; Rf value: 0.51 (CHCl3:MeOH, 9:1).
  • 3-(4-(2-(1H-Imidazol-1-yl)ethoxy)phenyl)-1-phenylprop-2-en-1-one (PS-9): Intermediate 1 was treated with pyrrolidine according to the general procedure to give the desired product PS-9 as light yellow, solid, yield 70%, m.p.: 93–96 °C; IR(KBr, cm−1): 1655 cm−1 (C=O, s); 1591 cm−1 (Ar C=C str, s), 1300–1100 cm−1 (C-N, m); 1H NMR (500 MHz, CDCl3, δ ppm): 8.02–7.99 (2H,m, ArH), 7.80–7.77 (1H, d, J = 15.55 Hz, CH), 7.62–7.61 (2H, d, J = 8.7 Hz, ArH), 7.59–7.56 (1H, t, J = 7.5 Hz, ArH), 7.51–7.48 (2H, t, J = 7.75, 7.3 Hz, ArH), 7.44–7.40 (1H, dd, J = 15.45, 7.3 Hz, -CH), 7.09–7.05 (1H, d, ArH), 7.05–7.03 (1H, m, ArH), 7.00–6.98 (2H, d, J = 8.7 Hz, ArH), 6.90–6.89 (1H, d, J = 8.7 Hz, ArH), 4.37–4.35 (2H, t, J = 4.95, 5.1 Hz, -CH2), 4.27–4.25 (2H, t, J = 5.1 Hz, -CH2); 13C NMR (500 MHz, CDCl3, δ ppm): 190.58, 160.59, 144.50, 138.48, 138.40, 132.72, 130.27, 128.60, 128.17, 128.07, 120.40, 120.14, 117.13, 115.10, 66.53, 46.45; MS (ESI) m/z = 319.14 (M + H)+; Rf value: 0.48 (CHCl3:MeOH, 9:1).
  • 3-(4-(2-(p-Methylpiperazin-1-yl)ethoxy)phenyl)-1-phenylprop-2-en-1-one (PS-10): Intermediate 1 was treated with N-methylpiperazine according to the general procedure to give the desired product PS-10 as white, solid, yield 60%, m.p.: 138-141 °C; IR(KBr, cm−1): 1655 cm−1 (C=O, s); 1590 cm−1 (Ar C=C str, s), 1300–1100 cm−1 (C-N, m); 1H NMR (500 MHz, CDCl3, δ ppm): 8.02–7.99 (2H,m, ArH), 7.80–7.76 (1H, dd, J = 15.65, 6.15 Hz, -CH), 7.63–7.55 (3H, m, ArH), 7.51–7.48 (2H, m, ArH), 7.44–7.39 (1H, dd, J = 9.6, 6 Hz, -CH), 7.00–6.93 (2H, dd, J = 8.7 Hz, ArH), 6.90–6.89 (1H, d, J = 8.7 Hz, ArH), 4.16–4.14 (2H, t, J = 5.8 Hz, -CH2), 2.85–2.83 (2H, t, J = 5.8, 5.01 Hz, -CH2), 2.64 (4H, s, -2(CH2)), 2.51 (4H, s, -2(CH2)), 2.31 (3H, s, CH3); 13C NMR (500 MHz, CDCl3, δ ppm): 190.59, 160.87, 144.66, 138.53, 132.56, 130.26, 128.59, 128.43, 127.76, 119.88, 115.04, 66.15, 57.01, 55.00, 53.50, 45.94; MS (ESI) m/z = 351.21 (M + H)+; Rf value: 0.24 (CHCl3:MeOH, 9:1).

3.5. Biological Activity

3.5.1. In Vitro Studies

In Vitro AChE Inhibition

The inhibitory potential of synthesized compounds was evaluated for brain AChE by the widely used Ellman et al. process [43,57,58]. The method involved using spectroscopic investigation at 450 nm. All the compounds with different concentrations were evaluated in triplicate including donepezil (standard AChE inhibitor).

AGE Inhibitory Activity

The synthesized compounds were assayed by the spectrofluorometric method for inhibition of glucose-mediated protein glycation. All the compounds and aminoguanidine (positive control) with different concentrations were evaluated in triplicate [74].

Free Radical Scavenging Activity

The activity was tested using the spectrophotometric Blois method [75].

3.5.2. In Vivo Studies

Animals

Wistar rats (200−250 g, either sex) were used for in vivo evaluation. The protocol was approved by IAEC, Chitkara University, Punjab, India (approval number: IAEC/CCP/22/01/PR-09).

Dementia Induction

To induce cognitive impairment in rats, solutions of Streptozotocin (STZ, 3 mg/kg) in artificial cerebro-spinal fluid (ACSF) were given as i.c.v. (intracerebroventricular) injections. The STZ injections were administered bilaterally on days 1 and 3 of the experimental protocol. The amount of STZ injected was adjusted to ensure that 10 µL was delivered to each site. A control group of rats was given i.c.v. injections of ACSF [76].

Experimental Groups

The rats used in the study were divided into six groups (n = 6). The treatment and cognitive investigation in the rats were performed as shown in Figure 9.
Group I (ACSF): Intracerebroventricular injections of ASCF (10 µL) on day 1 and day 3.
Group II (STZ + vehicle): On days 1 and 3, group II was given intracerebroventricular injections of STZ (3 mg/kg, 10 µL).
Group III (STZ + Donepezil): Consisted of STZ-treated rats that received donepezil (5 mg/kg; p.o.) from day 9 to day 22 [77].
Groups IV, V, and VI (STZ + PS10): Following intracerebroventricular injections of STZ, animal groups were administered different doses of PS10 (2, 5, and 10 mg/kg, p.o., respectively), from 9 to 22 days.

Behavioral Studies Using MWM (Morris Water Maze)

The MWM test was utilized by researchers to note the cognitive behavior of rats in terms of memory and learning [78]. The rats were trained from day 19 to 22, four times daily, to locate a hidden platform, and the time to locate the hidden platform was noted as ELT (escape latency time). Treatment with either donepezil or PS10 was administered 60 min before the training session. On day 23, the platform was deleted, and the same procedure was performed to test animal memory by noting the time spent by the rats as the target quadrant (TSTQ), with a limit of 120 s [79].

Brain Biochemical Estimations

After the behavioral experiment was completed, the rats were euthanized under mild anesthesia using cervical dislocation, and their brains were extracted. The homogenates were made in a buffer (pH 7.4) for further analysis. AChE activity [58], total protein levels [80], reduced GSH levels, and thiobarbituric acid reactive species (TBARS) levels [81] were measured using the brain homogenates.

3.6. Molecular Dynamic Simulation Studies

Using the Schrodinger suite 2021-1’s Desmond module and a Linux (Ubuntu) operating system, the molecular dynamics (MD) simulation was executed with the aid of an NVIDIA Quadro K2200 graphics card. A simulation period of 100 ns was conducted to investigate the thermodynamic stability of PS10 complexed with the AChE enzyme [82]. For stimulatory studies, the complex was built with the TIP3P explicit solvent system and centered with an orthorhombic periodic boundary box, followed by pH adjustment by Na+ and 0.15 M salt concentration. The built complex system minimization was carried out with the OPLSE_2005 force field. The NPT ensemble was a simulator with a fixed temperature of 300 K using the Nosé–Hoover Chain method, 1.0 fs time step, and 1.01325 bar. In order to investigate the trajectories, the simulation interaction graphs were constructed with a trajectory path of 4.8 and an energy interval of 1.2 ps. During the simulation, the structural dynamic patterns of the protein–ligand complex were assessed as the RMSD (root mean square deviation) for both components of the complex. The RMSD plot recorded the average change in the displacement of the backbone atoms of the protein and ligand structures. Additionally, the root mean square fluctuations (RMSF) for the protein and ligand in the complex were also computed and plotted the extent of the flexibility of each component. The RMSF represents the minimized fluctuations of the protein–ligand complex.

4. Conclusions

In this study, the objective was to assess the potential of the designed novel aminoethyl-O-chalcone-based derivatives having multi-functional potential against AD. The compounds were evaluated using in silico, in vitro, and in vivo assays to determine their activity against varied targets like AChE, AGE formation, and free radical scavenging. The design of the derivatives was based on the structural aspects of the biogenic molecule acetylcholine and the biological atmosphere within the active site of the AChE enzyme. The in silico pharmacokinetic profiles of the synthesized compounds revealed their drug-likeliness with good brain penetrability and gastrointestinal absorptivity. Most of the compounds exhibited significant inhibitory activities against AChE and AGE formation with additional antioxidant properties. The SAR analysis suggested that the potential for AChE inhibition was mainly attributed to the type of amino group present in the compounds. The compound PS10 with N-methylpiperazine substitution exhibited considerably higher AChE inhibitory potential than donepezil. The compound PS5 also exhibited some significant inhibition of AChE with respect to the reference. Additionally, the docking analysis showed that N-methylpiperazine (PS10) and piperidine (PS5) interacted with the crucial amino acids of the active site of the AChE enzyme. Moreover, these compounds had significant free radical scavenging ability and AGE product formation inhibition. Among all the synthesized aminoethyl-O-chalcone derivatives, PS5 and PS10 were found to be competent multifunctional molecules. The biochemical estimations also showed significant reductions in TBARS and GSH (oxidative stress markers) and AChE activities. These multifunctional aspects make these newly designed and synthesized compounds potential candidates for the development of drugs for AD and could be further explored to manage AD.

Supplementary Materials

The following supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/molecules28186579/s1.

Author Contributions

Methodology, P.S.; Validation, M.S.; Investigation, V.S.; Resources, T.G.S.; Data curation, T.S.; Supervision, M.S.; Funding acquisition, S.F.A. All authors have read and agreed to the published version of the manuscript.

Funding

Project number (RSPD2023R709), King Saud University, Riyadh, Saudi Arabia.

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

The data presented in this study are available within the article.

Acknowledgments

The authors acknowledge and extend their appreciation to the Researchers Supporting Project Number (RSPD2023R709), King Saud University, Riyadh, Saudi Arabia, for funding this study. The authors are also highly grateful to the Centre of Excellence, Drug Design and Molecular Modelling Centre, Chitkara College of Pharmacy, Chitkara University, Punjab, India, for providing resources for the completion of this research article.

Conflicts of Interest

The authors have no competing conflicts of interest to declare.

Sample Availability

Not applicable.

References

  1. Zhou, B.; Chengguo, X. Diverse molecular targets for chalcones with varied bioactivities. Med. Chem. 2015, 5, 388–404. [Google Scholar] [CrossRef] [PubMed]
  2. Gomes, M.N.; Muratov, E.N.; Pereira, M.; Peixoto, J.C.; Rosseto, L.P.; Cravo, P.V.; Andrade, C.H.; Neeves, B.J. Chalcone derivatives: Promising starting points for drug design. Molecules 2017, 22, 1210. [Google Scholar] [CrossRef] [PubMed]
  3. Singh, M.; Sharma, P.; Joshi, P.; Saini, K.; Sharma, A.; Puri, V.; Chander, J.; Singh, T.G.; Arora, S. Chalcones: A privileged scaffold with diverse biological activities. Plant Arch. 2020, 20, 3812–3819. [Google Scholar]
  4. Batovska, D.I.; Todorova, I.T. Trends in utilization of the pharmacological potential of chalcones. Curr. Clin. Pharmacol. 2010, 5, 1–29. [Google Scholar] [CrossRef] [PubMed]
  5. Sivakumar, P.M.; Prabhakar, P.K.; Doble, M. Synthesis, antioxidant evaluation, and quantitative structure–activity relationship studies of chalcones. Med. Chem. Res. 2011, 20, 482–492. [Google Scholar] [CrossRef]
  6. Go, M.L.; Wu, X.; Liu, X.L. Chalcones: An update on cytotoxic and chemoprotective properties. Curr. Med. Chem. 2005, 12, 483–499. [Google Scholar] [CrossRef]
  7. Romagnoli, R.; Baraldi, P.G.; Carrion, M.D.; Cara, C.L.; Cruz-Lopez, O.; Preti, D.; Tolomeo, M.; Grimaudo, S.; Di Cristina, A.; Zonta, N.; et al. Design, synthesis, and biological evaluation of thiophene analogues of chalcones. Bioorg. Med. Chem. 2008, 16, 5367–5376. [Google Scholar] [CrossRef]
  8. Orlikova, B.; Tasdemir, D.; Golais, F.; Dicato, M.; Diederich, M. Dietary chalcones with chemopreventive and chemotherapeutic potential. Genes Nutr. 2011, 6, 125–147. [Google Scholar] [CrossRef]
  9. Lee, J.S.; Kang, Y.; Kim, J.T.; Thapa, D.; Lee, E.S.; Kim, J.A. The anti-angiogenic and anti-tumor activity of synthetic phenylpropenone derivatives is mediated through the inhibition of receptor tyrosine kinases. Eur. J. Pharmacol. 2012, 677, 22–30. [Google Scholar] [CrossRef]
  10. Karthikeyan, C.; Moorthy, N.S.H.N.; Ramasamy, S.; Vanam, U.; Manivannan, E.; Karunagaran, D.; Trivedi, P. Advances in chalcones with anticancer activities. Recent Pat. Anti-Cancer Drug Discov. 2015, 10, 97–115. [Google Scholar] [CrossRef]
  11. Singh, M.; Sharma, P.; Singh, P.K.; Singh, T.G.; Saini, B. Medicinal potential of heterocyclic compounds from diverse natural sources for the management of cancer. Mini Rev. Med. Chem. 2020, 20, 942–957. [Google Scholar] [CrossRef] [PubMed]
  12. Hayat, F.; Moseley, E.; Salahuddin, A.; Van Zyl, R.L.; Azam, A. Antiprotozoal activity of chloroquinoline based chalcones. Eur. J. Med. Chem. 2011, 46, 1897–1905. [Google Scholar] [CrossRef] [PubMed]
  13. Sinha, S.; Batovska, D.I.; Medhi, B.; Radotra, B.D.; Bhalla, A.; Markova, N.; Sehgal, R. In vitro anti-malarial efficacy of chalcones: Cytotoxicity profile, mechanism of action and their effect on erythrocytes. Malar. J. 2019, 18, 421. [Google Scholar] [CrossRef] [PubMed]
  14. Bak, E.J.; Park, H.G.; Lee, C.H.; Lee, T.I.; Woo, G.H.; Na, Y.H.; Yoo, Y.J.; Cha, J.H. Effects of novel chalcone derivatives on α-glucosidase, dipeptidyl peptidase-4, and adipocyte differentiation in vitro. BMB Rep. 2011, 44, 410–414. [Google Scholar] [CrossRef]
  15. Mahapatra, D.K.; Asati, V.; Bharti, S.K. Chalcones and their therapeutic targets for the management of diabetes: Structural and pharmacological perspectives. Eur. J. Med. Chem. 2015, 92, 839–865. [Google Scholar] [CrossRef]
  16. Shukla, P.; Satyanarayana, M.; Verma, P.C.; Tiwari, J.; Dwivedi, A.P.; Srivastava, R.; Rehuja, N.; Srivastava, S.P.; Gautam, S.; Tamrakar, A.K.; et al. Chalcone-based aryloxypropanolamine as a potential antidiabetic and antidyslipidaemic agent. Curr. Sci. 2017, 25, 1675–1689. [Google Scholar] [CrossRef]
  17. Kontogiorgis, C.; Mantzanidou, M.; Hadjipavlou-Litina, D. Chalcones and their potential role in inflammation. Mini Rev. Med. Chem. 2008, 8, 1224–1242. [Google Scholar] [CrossRef]
  18. Bukhari, S.N.; Zhang, X.; Jantan, I.; Zhu, H.L.; Amjad, M.W.; Masand, V.H. Synthesis, molecular modeling, and biological evaluation of novel 1, 3-diphenyl-2-propen-1-one based pyrazolines as anti-inflammatory agents. Chem. Biol. Drug Des. 2015, 85, 729–742. [Google Scholar] [CrossRef]
  19. Singh, P.; Anand, A.; Kumar, V. Recent developments in biological activities of chalcones: A mini review. Eur. J. Med. Chem. 2014, 85, 758–777. [Google Scholar] [CrossRef]
  20. Zhuang, C.; Zhang, W.; Sheng, C.; Zhang, W.; Xing, C.; Miao, Z. Chalcone: A privileged structure in medicinal chemistry. Chem. Rev. 2017, 117, 7762–7810. [Google Scholar] [CrossRef]
  21. Mathew, B.; Haridas, A.; Uçar, G.; Baysal, I.; Joy, M.; Mathew, G.E.; Lakshmanan, B.; Jayaprakash, V. Synthesis, biochemistry, and computational studies of brominated thienyl chalcones: A new class of reversible MAO-B inhibitors. ChemMedChem 2016, 11, 1161–1171. [Google Scholar] [CrossRef]
  22. Zhang, X.; Rakesh, K.P.; Bukhari, S.N.; Balakrishna, M.; Manukumar, H.M.; Qin, H.L. Multi-targetable chalcone analogs to treat deadly Alzheimer’s disease: Current view and upcoming advice. Bioorg. Chem. 2018, 80, 86–93. [Google Scholar] [CrossRef]
  23. Mathew, B.; Parambi, D.G.; Sivasankarapillai, V.S.; Uddin, M.S.; Suresh, J.; Mathew, G.E.; Joy, M.; Marathakam, A.; Gupta, S.V. Perspective design of chalcones for the management of CNS disorders: A mini-review. CNS Neurol. Disord Drug Targets 2019, 18, 432–445. [Google Scholar] [CrossRef] [PubMed]
  24. Sharma, P.; Singh, M.; Mathew, B. An Update of Synthetic Approaches and Structure-Activity Relationships of Various Classes of Human MAO-B Inhibitors. ChemistrySelect 2021, 6, 1404–1429. [Google Scholar] [CrossRef]
  25. Sharma, P.; Singh, M. An ongoing journey of chalcone analogues as single and multi-target ligands in the field of Alzheimer’s disease: A review with structural aspects. Life Sci. 2023, 320, 121568. [Google Scholar] [CrossRef] [PubMed]
  26. Bhatia, S.; Rawal, R.; Sharma, P.; Singh, T.; Singh, M.; Singh, V. Mitochondrial dysfunction in Alzheimer’s disease: Opportunities for drug development. Curr. Neuropharmacol. 2022, 20, 675–692. [Google Scholar] [CrossRef] [PubMed]
  27. Craig, L.A.; Hong, N.S.; McDonald, R.J. Revisiting the cholinergic hypothesis in the development of Alzheimer’s disease. Neurosci. Biobehav. Rev. 2011, 35, 1397–1409. [Google Scholar] [CrossRef] [PubMed]
  28. He, Y.; Yao, P.F.; Chen, S.B.; Huang, Z.H.; Huang, S.L.; Tan, J.H.; Li, D.; Gu, L.Q.; Huang, Z.S. Synthesis and evaluation of 7,8-dehydrorutaecarpine derivatives as potential multifunctional agents for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2013, 63, 299–312. [Google Scholar] [CrossRef]
  29. Münch, G.; Thome, J.; Foley, P.; Schinzel, R.; Riederer, P. Advanced glycation end products in ageing and Alzheimer’s disease. Brain Res. Rev. 1997, 23, 134–143. [Google Scholar] [CrossRef]
  30. Grutzendler, J.; Morris, J.C. Cholinesterase inhibitors for Alzheimer’s disease. Drugs 2001, 61, 41–52. [Google Scholar] [CrossRef]
  31. Anand, P.; Singh, B. A review on cholinesterase inhibitors for Alzheimer’s disease. Arch. Pharm. Res. 2013, 36, 375–399. [Google Scholar] [CrossRef] [PubMed]
  32. Nistico, R.; Borg, J.J. Aducanumab for Alzheimer’s disease: A regulatory perspective. Pharmacol. Res. 2021, 171, 105754. [Google Scholar] [CrossRef] [PubMed]
  33. Tanoli, S.T.; Ramzan, M.; Hassan, A.; Sadiq, A.; Jan, M.S.; Khan, F.A.; Ullah, F.; Ahmad, H.; Bibi, M.; Mahmood, T.; et al. Design, synthesis and bioevaluation of tricyclic fused ring system as dual binding site acetylcholinesterase inhibitors. Bioorg. Chem. 2019, 83, 336–347. [Google Scholar] [CrossRef] [PubMed]
  34. Sanad, S.M.; Mekky, A.E. Novel nicotinonitrile-coumarin hybrids as potential acetylcholinesterase inhibitors: Design, synthesis, in vitro and in silico studies. J. Iran. Chem. Soc. 2021, 18, 213–224. [Google Scholar] [CrossRef]
  35. Behl, T.; Kaur, G.; Sehgal, A.; Bhardwaj, S.; Singh, S.; Buhas, C.; Judea-Pusta, C.; Uivarosan, D.; Munteanu, M.A.; Bungau, S. Multifaceted role of matrix metalloproteinases in neurodegenerative diseases: Pathophysiological and therapeutic perspectives. Int. J. Mol. Sci. 2021, 22, 1413. [Google Scholar] [CrossRef]
  36. Behl, T.; Kaur, D.; Sehgal, A.; Singh, S.; Sharma, N.; Zengin, G.; Andronie-Cioara, F.L.; Toma, M.M.; Bungau, S.; Bumbu, A.G. Role of monoamine oxidase activity in Alzheimer’s disease: An insight into the therapeutic potential of inhibitors. Molecules 2021, 26, 3724. [Google Scholar] [CrossRef]
  37. Mathew, B.; Suresh, J.; Anbazghagan, S.; Paulraj, J.; Krishnan, G.K. Heteroaryl chalcones: Mini review about their therapeutic voyage. Biomed. Prev. Nutr. 2014, 4, 451–458. [Google Scholar] [CrossRef]
  38. Mathew, B.; Uçar, G.; Mathew, G.E.; Mathew, S.; Kalatharakkal, P.P.; Moolayil, F.; Mohan, S.; Varghese Gupta, S. Monoamine Oxidase Inhibitory Activity: Methyl-versus Chlorochalcone Derivatives. ChemMedChem 2016, 11, 2649–2655. [Google Scholar] [CrossRef]
  39. Sang, Z.; Wang, K.; Zhang, P.; Shi, J.; Liu, W.; Tan, Z. Design, synthesis, in-silico and biological evaluation of novel chalcone derivatives as multi-function agents for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2019, 180, 238–252. [Google Scholar] [CrossRef]
  40. Climent, M.J.; Corma, A.; Iborra, S.; Primo, J. Base catalysis for fine chemicals production: Claisen-Schmidt condensation on zeolites and hydrotalcites for the production of chalcones and flavanones of pharmaceutical interest. J. Catal. 1995, 151, 60–66. [Google Scholar] [CrossRef]
  41. Polo, E.; Ibarra-Arellano, N.; Prent-Peñaloza, L.; Morales-Bayuelo, A.; Henao, J.; Galdámez, A.; Gutierrez, M. Ultrasound-assisted synthesis of novel chalcone, heterochalcone and bis-chalcone derivatives and the evaluation of their antioxidant properties and as acetylcholinesterase inhibitors. Bioorg. Chem. 2019, 90, 103034. [Google Scholar] [CrossRef] [PubMed]
  42. Dvir, H.; Silman, I.; Harel, M.; Rosenberry, T.; Sussman, J. Acetylcholinesterase: From 3D structure to function. Chem.-Biol. Interact. 2010, 187, 10–22. [Google Scholar] [CrossRef] [PubMed]
  43. Ellman, G.L.; Courtney, K.D.; Andres, V., Jr. Featherstone, R.M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem. Pharmacol. 1961, 7, 88–95. [Google Scholar] [CrossRef] [PubMed]
  44. Bagga, S.; Kumar, M. Current status of Alzheimer’s disease and pathological mechanisms investigating the therapeutic molecular targets. Curr. Mol. Med. 2023, 23, 492–508. [Google Scholar] [CrossRef]
  45. Wan Chik, M.; Ramli, N.A.; Mohamad Nor Hazalin, N.A.; Surindar Singh, G.K. Streptozotocin mechanisms and its role in rodent models for Alzheimer’s disease. Toxin Rev. 2023, 42, 491–502. [Google Scholar] [CrossRef]
  46. Silva, S.S.; Tureck, L.V.; Souza, L.C.; Mello-Hortega, J.V.; Piumbini, A.L.; Teixeira, M.D.; Furtado-Alle, L.; Vital, M.A.; Souza, R.L. Animal model of Alzheimer’s disease induced by streptozotocin: New insights about cholinergic pathway. Brain Res. 2023, 1799, 148175. [Google Scholar] [CrossRef]
  47. Kumar, A.; Singh, N. Calcineurin Inhibition and Protein Kinase A Activation Limits Cognitive Dysfunction and Histopathological Damage in a Model of Dementia of the Alzheimer’s Type. Curr. Neurovasc. Res. 2018, 15, 234–245. [Google Scholar] [CrossRef]
  48. Salkovic-Petrisic, M.; Knezovic, A.; Hoyer, S.; Riederer, P. What have we learned from the streptozotocin-induced animal model of sporadic Alzheimer’s disease, about the therapeutic strategies in Alzheimer’s research? J. Neural Transm. 2013, 120, 233–252. [Google Scholar] [CrossRef]
  49. Rani, R.; Kumar, A.; Jaggi, A.S.; Singh, N. Pharmacological investigations on efficacy of Phlorizin a sodium-glucose co-transporter (SGLT) inhibitor in mouse model of intracerebroventricular streptozotocin induced dementia of AD type. J. Basic Clin. Physiol. Pharmacol. 2021, 32, 1057–1064. [Google Scholar] [CrossRef]
  50. Hoyer, S. The aging brain. Changes in the neuronal insulin/insulin receptor signal transduction cascade trigger late-onset sporadic Alzheimer disease (SAD). A mini-review. J. Neural Transm. 2002, 109, 991–1002. [Google Scholar] [CrossRef]
  51. Akhtar, A.; Dhaliwal, J.; Sah, S.P. 7, 8-Dihydroxyflavone improves cognitive functions in ICV-STZ rat model of sporadic Alzheimer’s disease by reversing oxidative stress, mitochondrial dysfunction, and insulin resistance. Psychopharmacology 2021, 238, 1991–2009. [Google Scholar] [CrossRef]
  52. Wierońska, J.M.; Cieślik, P.; Burnat, G.; Kalinowski, L. Activation of Metabotropic Glutamate Receptor (mGlu2) and Muscarinic Receptors (M1, M4, and M5), Alone or in Combination, and Its Impact on the Acquisition and Retention of Learning in the Morris Water Maze, NMDA Expression and cGMP Synthesis. Biomolecules 2023, 13, 1064. [Google Scholar] [CrossRef]
  53. Singh, V.; Kaur, K.; Kaur, S.; Shri, R.; Singh, T.G.; Singh, M. Trimethoxyflavones from Ocimum basilicum L. leaves improve long term memory in mice by modulating multiple pathways. J. Ethnopharmacol. 2022, 295, 115438. [Google Scholar] [CrossRef] [PubMed]
  54. Othman, M.Z.; Hassan, Z.; Has, A.T.C. Morris water maze: A versatile and pertinent tool for assessing spatial learning and memory. Exp. Anim. 2022, 71, 264–280. [Google Scholar] [CrossRef] [PubMed]
  55. Andrade, M.K.; Souza, L.C.; Azevedo, E.M.; Bail, E.L.; Zanata, S.M.; Andreatini, R.; Vital, M.A. Melatonin reduces β-amyloid accumulation and improves short-term memory in streptozotocin-induced sporadic Alzheimer’s disease model. IBRO Neurosci. Rep. 2023, 14, 264–272. [Google Scholar] [CrossRef] [PubMed]
  56. Raheja, S.; Girdhar, A.; Kamboj, A.; Lather, V.; Pandita, D. Aegle marmelos leaf extract ameliorates the cognitive impairment and oxidative stress induced by intracerebroventricular streptozotocin in male rats. Life Sci. 2019, 221, 196–203. [Google Scholar] [CrossRef] [PubMed]
  57. Singh, M.; Silakari, O. Design, synthesis and biological evaluation of novel 2-phenyl-1-benzopyran-4-one derivatives as potential poly-functional anti-Alzheimer’s agents. RSC Adv. 2016, 6, 108411–108422. [Google Scholar] [CrossRef]
  58. Sukumaran, S.D.; Chee, C.F.; Viswanathan, G.; Buckle, M.J.; Othman, R.; Abd. Rahman, N.; Chung, L.Y. Synthesis, biological evaluation and molecular modelling of 2′-hydroxychalcones as acetylcholinesterase inhibitors. Molecules 2016, 21, 955. [Google Scholar] [CrossRef]
  59. Aggarwal, H.; Gupta, S.; Sharma, P.; Sharma, B.M.; Sharma, B. Neurobehavioral and neurobiochemical effect of atomoxetine and N-acetylcysteine in streptozotocin diabetes induced endothelial dysfunction and related dementia. Physiol. Behav. 2022, 249, 113767. [Google Scholar] [CrossRef]
  60. Plascencia-Villa, G.; Perry, G. Neuropathological changes provide insights into key mechanisms related to Alzheimer’s disease and related dementia. Am. J. Pathol. 2022, 192, 1340–1346. [Google Scholar] [CrossRef]
  61. Kara, B.; Gordon, M.N.; Gifani, M.; Dorrance, A.M.; Counts, S.E. Vascular and Nonvascular Mechanisms of Cognitive Impairment and Dementia. Clin. Geriatr. Med. 2023, 39, 109–122. [Google Scholar] [CrossRef] [PubMed]
  62. Singh, V.; Krishan, P.; Shri, R. Antioxidant-mediated neuroprotection by Allium schoenoprasum L. leaf extract against ischemia reperfusion-induced cerebral injury in mice. J. Basic Clin. Physiol. Pharmacol. 2018, 29, 403–410. [Google Scholar] [CrossRef] [PubMed]
  63. Beutler, E.; Duron, O.; Kelly, B.M. Improved method for the determination of blood glutathione. J. Lab. Clin. Med. 1963, 61, 882–888. [Google Scholar] [PubMed]
  64. Singh, M.; Kaur, M.; Singh, N.; Silakari, O. Exploration of multi-target potential of chromen-4-one based compounds in Alzheimer’s disease: Design, synthesis and biological evaluations. Bioorg. Med. Chem. 2017, 25, 6273–6285. [Google Scholar] [CrossRef] [PubMed]
  65. Ramezani, M.; Meymand, A.Z.; Khodagholi, F.; Kamsorkh, H.M.; Asadi, E.; Noori, M.; Rahimian, K.; Shahrbabaki, A.S.; Talebi, A.; Parsaiyan, H.; et al. A role for flavonoids in the prevention and/or treatment of cognitive dysfunction, learning, and memory deficits: A review of preclinical and clinical studies. Nutr. Neurosci. 2023, 26, 156–172. [Google Scholar] [CrossRef]
  66. Langdon, S.R.; Ertl, P.; Brown, N. Bioisosteric replacement and scaffold hopping in lead generation and optimization. Mol. Inform. 2010, 29, 366–385. [Google Scholar] [CrossRef]
  67. Dick, A.; Cocklin, S. Bioisosteric replacement as a tool in anti-HIV drug design. Pharmaceuticals 2020, 13, 36. [Google Scholar] [CrossRef]
  68. Shandil, R.; Panda, M.; Sadler, C.; Ambady, A.; Panduga, V.; Kumar, N.; Mahadevaswamy, J.; Sreenivasaiah, M.; Narayan, A.; Guptha, S.; et al. Scaffold morphing to identify novel DprE1 inhibitors with antimycobacterial activity. ACS Med. Chem. Lett. 2019, 10, 1480. [Google Scholar] [CrossRef]
  69. Shan, J.; Ji, C. MolOpt: A web server for drug design using bioisosteric transformation. Curr. Comput. Aided Drug Des. 2020, 16, 460–466. [Google Scholar] [CrossRef]
  70. Daina, A.; Michielin, O.; Zoete, V. SwissADME: A free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci. Rep. 2017, 7, 42717. [Google Scholar] [CrossRef]
  71. Lipinski, C.A. Lead-and drug-like compounds: The rule-of-five revolution. Drug Discov. Today Technol. 2004, 1, 337–341. [Google Scholar] [CrossRef] [PubMed]
  72. Tran, T.-S.; Le, M.-T.; Tran, T.-D.; Tran, T.-H.; Thai, K.-M. Design of Curcumin and Flavonoid Derivatives with Acetylcholinesterase and Beta-Secretase Inhibitory Activities Using in Silico Approaches. Molecules 2020, 25, 3644. [Google Scholar] [CrossRef] [PubMed]
  73. Bao, L.-Q.; Baecker, D.; Mai Dung, D.T.; Phuong Nhung, N.; Thi Thuan, N.; Nguyen, P.L.; Phuong Dung, P.T.; Huong, T.T.L.; Rasulev, B.; Casanola-Martin, G.M.; et al. Development of Activity Rules and Chemical Fragment Design for In Silico Discovery of AChE and BACE1 Dual Inhibitors against Alzheimer’s Disease. Molecules 2023, 28, 3588. [Google Scholar] [CrossRef] [PubMed]
  74. Matsuura, N.; Aradate, T.; Sasaki, C.; Kojima, H.; Ohara, M.; Hasegawa, J.; Ubukata, M. Screening system for the Maillard reaction inhibitor from natural product extracts. J. Health Sci. 2002, 48, 520–526. [Google Scholar] [CrossRef]
  75. Blois, M.S. Antioxidant determinations by the use of a stable free radical. Nature 1958, 181, 1199–1200. [Google Scholar] [CrossRef]
  76. Alexandre-Silva, V.; Pereira, G.C.; Ribeiro, A.M. Therapeutic approaches using natural substances on the streptozotocin-induced animal model of sporadic Alzheimer’s disease: A systematic review. Adv. Trad. Med. 2023, 1–25. [Google Scholar] [CrossRef]
  77. Knezovic, A.; Osmanovic-Barilar, J.; Curlin, M.; Hof, P.R.; Simic, G.; Riederer, P.; Salkovic-Petrisic, M. Staging of cognitive deficits and neuropathological and ultrastructural changes in streptozotocin-induced rat model of Alzheimer’s disease. J. Neural Transm. 2015, 122, 577–592. [Google Scholar] [CrossRef]
  78. Morris, R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods 1984, 11, 47–60. [Google Scholar] [CrossRef]
  79. Singh, V.; Krishan, P.; Shri, R. Amelioration of ischaemia reperfusion-induced cerebral injury in mice by liposomes containing Allium cepa fraction administered intranasally. Artif. Cells Nanomed. Biotechnol. 2018, 46, 982–992. [Google Scholar] [CrossRef]
  80. Lowry, O.H.; Rosebrough, N.J.; Farr, A.L.; Randall, R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 1951, 193, 265–275. [Google Scholar] [CrossRef]
  81. Ohkawa, H. Assay for lipid peroxidation in animal tissues by thiobarbituric acid reaction. Anal. Biochem. 1979, 95, 351–358. [Google Scholar] [CrossRef] [PubMed]
  82. Bowers, K.J.; Chow, E.; Xu, H.; Dror, R.O.; Eastwood, M.P.; Gregersen, B.A.; Klepeis, J.L.; Kolossvary, I.; Moraes, M.A.; Sacerdoti, F.D.; et al. Scalable algorithms for molecular dynamics simulations on commodity clusters. In Proceedings of the 2006 ACM/IEEE Conference on Supercomputing, Tampa, FL, USA, 11–17 November 2006; Volume 11, p. 84. [Google Scholar] [CrossRef]
Molecules 28 06579 g001
Figure 1. Chalcone-based multifunctional molecules with varied substitutions.
Figure 1. Chalcone-based multifunctional molecules with varied substitutions.
Molecules 28 06579 g001
Molecules 28 06579 g002
Figure 2. Five bioisosteric sites and the corresponding bioisosteres.
Figure 2. Five bioisosteric sites and the corresponding bioisosteres.
Molecules 28 06579 g002
Molecules 28 06579 g003
Figure 3. Interactions of compounds PS5 and PS10 within the binding site of AChE (1EVE): (a,c) 2D profile of different interactions of PS5 and PS10 with TcAChE, and (b,d) 3D profile of binding of PS5 and PS10 with TcAChE.
Figure 3. Interactions of compounds PS5 and PS10 within the binding site of AChE (1EVE): (a,c) 2D profile of different interactions of PS5 and PS10 with TcAChE, and (b,d) 3D profile of binding of PS5 and PS10 with TcAChE.
Molecules 28 06579 g003
Molecules 28 06579 sch001
Scheme 1. Synthesis of aminoethyl-O-chalcone derivatives PS (1–10) with reaction conditions and reagents.
Scheme 1. Synthesis of aminoethyl-O-chalcone derivatives PS (1–10) with reaction conditions and reagents.
Molecules 28 06579 sch001
Molecules 28 06579 g004
Figure 4. Evaluation of different interventions on ELT at days 1 and 4 employing MWM for memory evaluation. a p < 0.05 vs. day 1 escape latency of vehicle control group; b p < 0.05 vs. day 4 escape latency of vehicle control group; c p < 0.05 vs. day 4 escape latency of STZ + vehicle group; d p < 0.05 vs. day 4 escape latency of STZ + donepezil group.
Figure 4. Evaluation of different interventions on ELT at days 1 and 4 employing MWM for memory evaluation. a p < 0.05 vs. day 1 escape latency of vehicle control group; b p < 0.05 vs. day 4 escape latency of vehicle control group; c p < 0.05 vs. day 4 escape latency of STZ + vehicle group; d p < 0.05 vs. day 4 escape latency of STZ + donepezil group.
Molecules 28 06579 g004
Molecules 28 06579 g005
Figure 5. Effect of PS10 for TSTQ by rat in the MWM. a p < 0.05 vs. q1, q2 and q3 of vehicle control group; b p < 0.05 vs. q4 of vehicle control group; c p < 0.05 vs. q4 of STZ + vehicle group; d p < 0.05 vs. q4 of STZ + donepezil group.
Figure 5. Effect of PS10 for TSTQ by rat in the MWM. a p < 0.05 vs. q1, q2 and q3 of vehicle control group; b p < 0.05 vs. q4 of vehicle control group; c p < 0.05 vs. q4 of STZ + vehicle group; d p < 0.05 vs. q4 of STZ + donepezil group.
Molecules 28 06579 g005
Molecules 28 06579 g006
Figure 6. PS10′s effect on (A) brain AChE activity, (B) brain GSH level, and (C) brain TBARS levels of rats. a p < 0.05 vs. vehicle control; b p < 0.05 vs. STZ; c p < 0.05 vs. donepezil.
Figure 6. PS10′s effect on (A) brain AChE activity, (B) brain GSH level, and (C) brain TBARS levels of rats. a p < 0.05 vs. vehicle control; b p < 0.05 vs. STZ; c p < 0.05 vs. donepezil.
Molecules 28 06579 g006
Molecules 28 06579 g007
Figure 7. Detailed interactions of PS10 with AChE enzyme: (A) post-MD interactions (H-bond, hydrophobic, and ionic) of PS-10 with AChE; (B) AChE–PS10 contacts summary during 100 ns MD simulation; (C) RMSD plot; (D) RMSF plot interacting protein residues.
Figure 7. Detailed interactions of PS10 with AChE enzyme: (A) post-MD interactions (H-bond, hydrophobic, and ionic) of PS-10 with AChE; (B) AChE–PS10 contacts summary during 100 ns MD simulation; (C) RMSD plot; (D) RMSF plot interacting protein residues.
Molecules 28 06579 g007
Molecules 28 06579 g008
Figure 8. Various steps involved in the current study.
Figure 8. Various steps involved in the current study.
Molecules 28 06579 g008
Molecules 28 06579 g009
Figure 9. The flow of experimental protocol for in vivo studies.
Figure 9. The flow of experimental protocol for in vivo studies.
Molecules 28 06579 g009
Table 1. ADME profile and the physicochemical parameters of the aminoethyl-O-chalcone derivatives.
Table 1. ADME profile and the physicochemical parameters of the aminoethyl-O-chalcone derivatives.
S. No.CompoundMol.Wt.HB AccHB DonTPSAConsensus Log PAli Log SRule of FiveBrain PermeantGI Absorption
1PS-2295.383029.543.37−3.380YesHigh
2PS-3323.433029.544.02−4.140YesHigh
3PS-4371.473029.544.7−5.560YesHigh
4PS-5335.443029.544.1−4.880YesHigh
5PS-6336.434141.572.9−3.580YesHigh
6PS-7337.414038.773.19−3.820YesHigh
7PS-8321.413029.543.79−4.520YesHigh
8PS-9318.373044.123.22−4.240YesHigh
9PS-10350.454032.783.15−3.880YesHigh
10PS-11364.484032.783.48−4.260YesHigh
11PS-12349.473029.544.39−5.260YesHigh
12PS-13378.514032.783.8−4.620YesHigh
13PS-14363.493029.544.72−5.630YesHigh
14PS-15392.534032.784.13−4.990YesHigh
15PS-16377.523029.545.03−60YesHigh
16PS-17406.564032.784.45−5.370YesHigh
17PS-18391.553029.545.35−6.370YesHigh
18PS-19380.485042.013.18−4.040YesHigh
19PS-20410.516051.243.14−4.210YesHigh
20PS-21440.537060.473.13−4.370YesHigh
21PS-22325.44038.773.48−4.170YesHigh
22PS-23351.444038.773.77−4.680YesHigh
23PS-24365.474038.774.06−5.060YesHigh
24PS-25366.455150.82.86−3.740YesHigh
25PS-26380.485042.013.18−4.040YesHigh
26PS-27295.383029.543.37−3.380YesHigh
27PS-28353.454038.774.1−4.910YesHigh
28PS-29379.494038.774.37−5.420YesHigh
29PS-30339.434038.773.78−4.550YesHigh
30PS-31379.494038.774.43−5.420YesHigh
31PS-32353.454038.774.14−4.930YesHigh
32PS-33367.4450483.2−3.980YesHigh
33PS-34339.434038.773.8−4.560YesHigh
34PS-35387.473038.774.68−6.020YesHigh
35PS-36367.484038.774.42−5.30YesHigh
36PS-37379.494038.774.3−5.50YesHigh
37PS-38381.4650483.52−4.350YesHigh
38PS-39353.454038.774.1−4.920YesHigh
39PS-40337.414038.773.71−4.790YesHigh
40PS-41353.454038.774.16−5.10YesHigh
Table 2. The docking scores with their interactions with enzyme 4.
Table 2. The docking scores with their interactions with enzyme 4.
Compound IDStructureDocking Score (Kcal/mol)Interactions
PS1Molecules 28 06579 i001−31.90His440, Ser200, Tyr121, Trp279
PS2Molecules 28 06579 i002−49.39His440, Trp84, Trp279, Ser200, Tyr121, Arg289, Gly119
PS3Molecules 28 06579 i003−51.43His440, Ser200, Trp84, Trp279, Tyr121, Arg289, Gly119
PS4Molecules 28 06579 i004−56.92Trp84, Phe330, Trp279, Arg289, Tyr130, His440, Ser200, Gly119
PS5Molecules 28 06579 i005−52.28His440, Phe330, Trp84, Trp279, Arg289, Ser200, Tyr121, Gly119, Asp72
PS6Molecules 28 06579 i006−51.08His440, Trp84, Phe330, Arg289, Ser200, Tyr121, Trp279, Gly119
PS7Molecules 28 06579 i007−51.01Trp84, Ph330, Trp279, His440, Ser 200, Tyr121, Gly119, Arg289
PS8Molecules 28 06579 i008−52.83His440, Trp84, Phe330, Ser200, Tyr121, Trp279, Arg289
PS9Molecules 28 06579 i009−53.45His440, Trp279, Trp84, Ser200, Tyr121, Phe330
PS10Molecules 28 06579 i010−63.75His440, Asp72, Trp279, Trp84, Ser200, Tyr121, Arg289, Phe330
DonepezilMolecules 28 06579 i011−51.89Trp84, Tyr121, His440, Ser200, Trp279, Phe330
Table 3. The AChE inhibition, AGE formation inhibition, and radical scavenging activities.
Table 3. The AChE inhibition, AGE formation inhibition, and radical scavenging activities.
Molecules 28 06579 i012Molecules 28 06579 i013
PS1PS (2–10)
C. No.-NR1R2AChE Inhibitory Activity
(Mean n ± SD, nM) 		AGE Inhibitory Activity
(Mean n ± SD, µM) 		Radical Scavenging Activity
(Mean n ± SD, nM)
PS1-36.47 ± 0.4243.6 ± 0.0822.41 ± 0.4
PS2Dimethylamino52.51 ± 0.2068.6 ± 0.2349.85 ± 0.11
PS3Diethylamino47.5 ± 0.2167.3 ± 0.3349.41 ± 0.22
PS4N-benzyl(methyl)amino48.8 ± 0.0469.39 ± 0.249.48 ± 0.21
PS5Piperidine19.71 ± 0.355.3 ± 0.234.38 ± 0.4
PS6Piperazine21.4 ± 0.864.51 ± 0.246.7 ± 0.24
PS7Morpholine22.72 ± 0.1351.2 ± 0.837.65 ± 0.24
PS8Pyrrolidine32.72 ± 0.1265.41 ± 0.3648.64 ± 0.18
PS9Imidazole26.3 ± 0.365.7 ± 0.1748.58 ± 0.42
PS104-Methylpiperazine15.3 ± 0.7249.85 ± 0.1322.83 ± 0.2
Std.Donepezil15.68 ± 0.26----
Std.Ascorbic acid----21.7 ± 0.08
Std.Aminoguanidine (AG)--44.3 ± 0.12--
n = 3.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sharma, P.; Singh, M.; Singh, V.; Singh, T.G.; Singh, T.; Ahmad, S.F. Recent Development of Novel Aminoethyl-Substituted Chalcones as Potential Drug Candidates for the Treatment of Alzheimer’s Disease. Molecules 2023, 28, 6579. https://doi.org/10.3390/molecules28186579

AMA Style

Sharma P, Singh M, Singh V, Singh TG, Singh T, Ahmad SF. Recent Development of Novel Aminoethyl-Substituted Chalcones as Potential Drug Candidates for the Treatment of Alzheimer’s Disease. Molecules. 2023; 28(18):6579. https://doi.org/10.3390/molecules28186579

Chicago/Turabian Style

Sharma, Pratibha, Manjinder Singh, Varinder Singh, Thakur Gurjeet Singh, Tanveer Singh, and Sheikh F. Ahmad. 2023. "Recent Development of Novel Aminoethyl-Substituted Chalcones as Potential Drug Candidates for the Treatment of Alzheimer’s Disease" Molecules 28, no. 18: 6579. https://doi.org/10.3390/molecules28186579

Article Metrics

Back to TopTop